Subscribe to RSS
Download PDF
DOI: 10.1007/s40556-020-00275-2
Anticancer Agent Gefitinib and Congenital Anomalies
Abstract
Congenital abnormalities caused by human teratogenic drugs account for less than 1% of total congenital abnormalities. We report the first case of multiple anomalies associated with antenatal exposure to the anticancer agent Gefitinib. The patient conceived while she was on tablet Gefitinib 250 mg once a day for stage IV adenocarcinoma of lungs. The first scan done at 29 weeks 2 days showed liquor amnii on the upper limit of normal, single umbilical artery, left sided congenital diaphragmatic hernia, ventriculoseptal defect and left radial ray defect. The patient had a preterm delivery after one week and she refused autopsy. It is important to advise patients regarding contraception while undergoing chemotherapy as there is an increased risk of drug induced fetal malformations.
Publication History
Received: 16 July 2020
Accepted: 30 October 2020
Article published online:
05 May 2023
© 2020. Society of Fetal Medicine. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India